Boston Scientific Co. (NYSE:BSX) Shares Sold by Nottingham Advisors Inc.

Nottingham Advisors Inc. decreased its holdings in Boston Scientific Co. (NYSE:BSX) by 61.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,000 shares of the medical equipment provider’s stock after selling 14,256 shares during the quarter. Nottingham Advisors Inc.’s holdings in Boston Scientific were worth $804,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BSX. Atom Investors LP acquired a new position in shares of Boston Scientific during the third quarter valued at about $412,000. Benjamin Edwards Inc. increased its stake in Boston Scientific by 5,065.7% during the 3rd quarter. Benjamin Edwards Inc. now owns 14,154 shares of the medical equipment provider’s stock valued at $1,186,000 after purchasing an additional 13,880 shares in the last quarter. Ascent Group LLC raised its stake in Boston Scientific by 10.8% in the 3rd quarter. Ascent Group LLC now owns 8,288 shares of the medical equipment provider’s stock worth $695,000 after acquiring an additional 808 shares during the last quarter. Hilltop Holdings Inc. raised its stake in shares of Boston Scientific by 117.2% in the third quarter. Hilltop Holdings Inc. now owns 14,016 shares of the medical equipment provider’s stock worth $1,175,000 after purchasing an additional 7,564 shares during the last quarter. Finally, HighTower Advisors LLC raised its position in Boston Scientific by 28.2% during the 3rd quarter. HighTower Advisors LLC now owns 109,978 shares of the medical equipment provider’s stock worth $9,241,000 after buying an additional 24,180 shares during the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Stock Performance

NYSE BSX opened at $100.07 on Thursday. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. The stock’s 50 day simple moving average is $102.20 and its 200-day simple moving average is $93.48. The company has a market cap of $148.01 billion, a PE ratio of 80.06, a price-to-earnings-growth ratio of 2.79 and a beta of 0.77. Boston Scientific Co. has a 1-year low of $66.80 and a 1-year high of $107.17.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. As a group, equities research analysts anticipate that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling

In other Boston Scientific news, EVP John Bradley Sorenson sold 6,528 shares of the business’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $104.97, for a total transaction of $685,244.16. Following the transaction, the executive vice president now owns 26,449 shares of the company’s stock, valued at approximately $2,776,351.53. The trade was a 19.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of the company’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $104.25, for a total value of $487,368.75. Following the completion of the sale, the executive vice president now owns 28,454 shares of the company’s stock, valued at approximately $2,966,329.50. The trade was a 14.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 133,183 shares of company stock worth $13,948,476. 0.50% of the stock is owned by insiders.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Stifel Nicolaus increased their price objective on shares of Boston Scientific from $100.00 to $115.00 and gave the stock a “buy” rating in a research note on Thursday, February 6th. Canaccord Genuity Group lifted their price objective on Boston Scientific from $98.00 to $101.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Barclays upped their target price on Boston Scientific from $111.00 to $118.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. Wells Fargo & Company lifted their price target on Boston Scientific from $100.00 to $118.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Finally, Deutsche Bank Aktiengesellschaft upgraded Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price objective on the stock in a research report on Friday, January 10th. Two investment analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $108.91.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.